You are here

  • Home
  • Archive
  • Volume 4, Issue 1
  • Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

Article metrics

Article menu

Download PDFPDF

Case Report
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2026

AbstractFullPdf
Dec 2019220
Jan 2020551
Feb 202011112
Mar 202013130
Apr 2020994
May 202013132
Jun 202025255
Jul 202026268
Aug 2020441
Sep 202026263
Oct 202018181
Nov 202019181
Dec 2020991
Jan 202114143
Feb 2021882
Mar 202116163
Apr 2021553
May 2021994
Jun 202118184
Jul 202119193
Aug 202111114
Sep 202114140
Oct 202124241
Nov 202119190
Dec 202124241
Jan 202249501
Feb 202280801
Mar 202224253
Apr 202223256
May 202243432
Jun 202232320
Jul 202221221
Aug 202230302
Sep 2022343512
Oct 202222220
Nov 2022192115
Dec 202222231
Jan 202326261
Feb 202325252
Mar 202320214
Apr 202316174
May 202313134
Jun 202312121
Jul 202313139
Aug 202315153
Sep 202325254
Oct 202317172
Nov 202333332
Dec 202329291
Jan 202446475
Feb 202436367
Mar 2024252511
Apr 202422226
May 202425253
Jun 202435347
Jul 202424257
Aug 202423225
Sep 202426267
Oct 202422229
Nov 2024434410
Dec 202449493
Jan 2025272711
Feb 202524246
Mar 202531319
Apr 202546465
May 202540417
Jun 202524243
Jul 2025220
Mar 2026110
Total15751587259